COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

COSCIENS Biopharma Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Total Receivables
$1.6m
CAGR 3-Years
-9%
CAGR 5-Years
15%
CAGR 10-Years
5%
Theratechnologies Inc
TSX:TH
Total Receivables
$11.4m
CAGR 3-Years
-4%
CAGR 5-Years
-1%
CAGR 10-Years
13%
Repare Therapeutics Inc
NASDAQ:RPTX
Total Receivables
$8.3m
CAGR 3-Years
-17%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Receivables
$30.7m
CAGR 3-Years
-10%
CAGR 5-Years
95%
CAGR 10-Years
77%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Total Receivables
$812k
CAGR 3-Years
-31%
CAGR 5-Years
-13%
CAGR 10-Years
10%
Spectral Medical Inc
TSX:EDT
Total Receivables
CA$433k
CAGR 3-Years
76%
CAGR 5-Years
6%
CAGR 10-Years
-5%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Total Receivables?
Total Receivables
1.6m USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Total Receivables amounts to 1.6m USD.

What is COSCIENS Biopharma Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
5%

Over the last year, the Total Receivables growth was -20%. The average annual Total Receivables growth rates for COSCIENS Biopharma Inc have been -9% over the past three years , 15% over the past five years , and 5% over the past ten years .

Back to Top